Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sato Pharm. Launches Switch OTC Version of Clotrimazole for Vaginal Candidiasis
May 16, 2011
- Takeda Announces Equity Investment in Fate Therapeutics of US
May 16, 2011
- Once-Daily Mirapex Approved for Parkinson's Disease: NBI
May 16, 2011
- Daiichi Sankyo to Launch AD Treatment MEMARY in June
May 16, 2011
- Pancreatic Digestive Enzyme LipaCreon Approved: Abbott Japan, Eisai
May 16, 2011
- Legal Prescription Receipt Rate Exceeds 65%: JPA
May 16, 2011
- Production to Resume at Takahagi Tech Center in Oct.: Astellas
May 16, 2011
- Tramcet Combination Tab Approved for Relief of Chronic Pain: Janssen
May 16, 2011
- Industry Concerned About Possibility of Consecutive NHI Price Revisions
May 16, 2011
- Takara Bio Aims for Sales of ¥22,700 Mil. in FY2013
May 16, 2011
- Suprane Approved for Inhalation Anesthesia: Baxter
May 16, 2011
- Taiyo Reportedly Seeking Strategic Alliance with Teva
May 16, 2011
- Alfresa HD Revises Profit Forecasts Downward Due to Losses Caused by Quake
May 16, 2011
- Genzyme's Thymoglobulin Obtains Additional Indication
May 16, 2011
- DSP, CiRA to Jointly Develop Drugs for a Rare, Intractable Disease
May 16, 2011
- MatsumotoKiyoshi HD Maintains “A-”Rating: R&I
May 16, 2011
- New Dosage Approved for Shionogi's Finibax
May 16, 2011
- Wakamoto's Mid-term Management Plan Calls For Return to Black in FY2011
May 2, 2011
- Korosho to Introduce Relief Program for Families of Patients Who Die due to Anticancer Drug-related Adverse Effects
May 2, 2011
- Meiji Seika Pharma Aims at Sales of ¥200 Bil. in FY2020
May 2, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…